Secukinumab demonstrates efficacy, safety and tolerability upon administration by 2  mL autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE , a randomized, placebo‐controlled trial

2021 ◽  
Author(s):  
Bardur Sigurgeirsson ◽  
John Browning ◽  
Stephen Tyring ◽  
Jacek C. Szepietowski ◽  
Raquel Rivera‐Díaz ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Controlled Trial ◽  
Adult Patients

Pharmacoeconomic analysis of using genetically engineered biologic drugs for treating adult patients with moderate to severe plaque psoriasis in the Russian Federation

2020 ◽  
pp. 57-65
Author(s):  
Maksim Frolov ◽  
Vladimir Rogov ◽  
Alla Salasyuk
Keyword(s):  
Plaque Psoriasis ◽  
Impact Analysis ◽  
Pharmacoeconomic Analysis ◽  
Certolizumab Pegol ◽  
Genetically Engineered ◽  
Adult Patients ◽  
Comparable Efficacy ◽  
Biologic Drugs ◽  
Severe Plaque Psoriasis ◽  
Cost Minimisation Analysis

The aim of the study was to assess clinical and economic effectiveness of netakimab compared to other genetically engineered biologic drugs (infliximab, adalimumab, etanercept, ustekinumab, secukinumab, ixekizumab, certolizumab pegol) for the treatment of adult patients with moderate to severe plaque psoriasis. We have conducted cost-benefit analysis, cost-minimisation analysis, and budget impact analysis. We have considered only direct medical costs. The results of the study show that netakimab has higher or comparable efficacy and significantly lower costs compared to other biologic drugs, that makes it the most preferable treatment option for patients with moderate to severe plaque psoriasis. Use of netakimab in clinical practice will significantly reduce budget expenditures and increase patient access to biologic therapy.

A Randomized Single Blind Controlled Trial of Combination Therapy (Spironolactone and Sitagliptin) in Hospitalized Adult Patients with Covid-19

2021 ◽  
Author(s):  
Kamyar Asadipooya ◽  
Farhad Abbasi ◽  
Reuben Adatorwovor ◽  
Mohammad Ali Davarpanah ◽  
Yasaman Mansoori ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Controlled Trial ◽  
Adult Patients ◽  
Single Blind

scholarly journals Lovastatin for adult patients with dengue: protocol for a randomised controlled trial

Trials ◽  
2012 ◽  
Vol 13 (1) ◽  
Author(s):  
James Whitehorn ◽  
Nguyen Van Vinh Chau ◽  
Nguyen Thanh Truong ◽  
Luong Thi Hue Tai ◽  
Nguyen Van Hao ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Adult Patients ◽  
Randomised Controlled

PS-026 Relative safety of biological drugs in the maintenance phase in adult patients with moderate to severe plaque psoriasis

2014 ◽  
Vol 21 (Suppl 1) ◽  
pp. A154.1-A154
Author(s):  
M Galván-Banqueri ◽  
A Castillo-Muñoz ◽  
R Ubago-Pérez ◽  
L Abdel-Kader Martín ◽  
C Beltrán-Calvo ◽  
...  
Keyword(s):  
Plaque Psoriasis ◽  
Maintenance Phase ◽  
Adult Patients ◽  
Biological Drugs ◽  
Severe Plaque Psoriasis ◽  
Relative Safety

290 COMPARATIVE EFFICACY OF CORTICOSTEROIDS FORMULATIONS FOR THE MANAGEMENT OF EOSINOPHILIC OESOPHAGITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS.

2020 ◽  
Vol 33 (Supplement_1) ◽  
Author(s):  
C Ma ◽  
B Feagan ◽  
D Claveau ◽  
L Landry ◽  
V Baribeau ◽  
...  
Keyword(s):  
Topical Corticosteroid ◽  
Controlled Trial ◽  
Meta Analysis ◽  
Adult Patients ◽  
Eosinophilic Oesophagitis ◽  
High Power Field ◽  
Topical Corticosteroids ◽  
Randomized Controlled ◽  
First Choice ◽  
Histological Remission

Abstract   Topical corticosteroids are the foundation of pharmacologic treatment for eosinophilic oesophagitis (EoE) and administered mainly as nebulized swallowed fluticasone or budesonide viscous solution (BVS). Recently, a budesonide orodispersible tablet (BOT) has been approved for the treatment of EoE. The ideal formulation of topical corticosteroid delivery is unclear. Therefore, we aimed to compare the efficacy of BOT with other topical corticosteroid formulations for achieving histological remission in adult patients with EoE in a network meta-analysis (NMA). Methods A systematic literature review was performed using Medline and EMBASE from 1990 to July 2019. Eligible studies evaluated adult patients with a diagnosis of EoE treated with a topical corticosteroid in a randomized controlled trial. The outcome of interest was the proportion of patients achieving induction of histological remission (peak esophageal eosinophil count <5 eosinophils/high-power field). Direct comparisons were performed using the Mantel–Haenszel method and an NMA was performed using a fixed effect Bayesian framework with Markov Chain Monte Carlo simulations. Heterogeneity between studies was analyzed using the Cochrane Q test and consistency was verified. Results The search yielded 321 references and 6 (447 patients) were included in the quantitative summary. In the NMA, all formulations of topical corticosteroids were associated with greater histological remission rates than placebo. BOT was associated with a significantly higher rate of histological remission compared to BVS (odds ratio [OR] = 4.9; 95% credible interval [CrI] = 1.4,19.1), fluticasone (OR = 7.4; 95%CrI = 1.7,34.5), nebulized swallowed budesonide (NSB) (OR = 25.0; 95%CrI = 2.9,247.2) and placebo (OR = 387.6; 95%CrI = 97.5,2275.6). Similar trends were shown in direct comparisons. Analysis of the ranking of treatment options based on probability of effectiveness found BOT to be most probable followed by BVS, fluticasone, NSB, and placebo, consecutively. Conclusion This NMA of randomized controlled trials suggests that BOT is significantly more likely to achieve histological remission in adult patients with EoE compared to BVS, fluticasone, and NSB. We hypothesize that the superiority of BOT is related to increased contact time and targeting all inflammatory sites in the oesophagus, in contrast to other formulations. This NMA suggest that BOT is the first choice therapy amongst topical corticosteroids for the management of EoE.

Sign in / Sign up

Export Citation Format

Share Document